Arcellx, Inc. - Common Stock (NQ:ACLX)

115.07 UNCHANGED

Last Price Updated: 4:15 PM EDT, Apr 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

What 5 Analyst Ratings Have To Say About Arcellx ↗

March 30, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023 ↗

March 14, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023 ↗

February 13, 2023

Via Benzinga

Where Arcellx Stands With Analysts ↗

December 12, 2022

Via Benzinga

Why Is Arcellx (ACLX) Stock Up 25% Today? ↗

December 09, 2022

ACLX stock is usually under the radar, but today it's in the spotlight as Arcellx reveals a team-up with a well-known biotech business.

Via InvestorPlace

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

January 30, 2023

From Gilead Sciences, Inc. and Arcellx, Inc.

Via Business Wire

20 Favorite Biotech & Medical Stocks For 2023 ↗

December 28, 2022

The way these stocks are setting up, many of them look great and will be at the forefront this coming year.

Via Talk Markets

Dow Tumbles 100 Points; Silver Rises Over 2% ↗

December 09, 2022

U.S. stocks traded mostly lower toward the end of trading with the Dow Jones dropping 100 points on Friday

Via Benzinga

US Stocks Turn Higher; Nasdaq Rises 40 Points ↗

December 09, 2022

U.S. stocks traded slightly midway through trading with the Nasdaq gaining over 40 points on Friday

Via Benzinga

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗

December 19, 2022

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

Via Benzinga

Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences ↗

December 09, 2022

The company inked a deal worth $325 million and up to $3.9 billion in milestones.

Via Investor's Business Daily

Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session ↗

December 09, 2022

Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.

Via Benzinga

US Stocks Edge Lower; Producer Prices Increase Higher Than Expected ↗

December 09, 2022

U.S. stocks traded slightly lower this morning following the release of PPI data

Via Benzinga

Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate ↗

December 09, 2022

Via Benzinga

Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

December 09, 2022

From Gilead Sciences, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

December 08, 2022

Via Benzinga

Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock ↗

October 27, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2022 ↗

October 27, 2022

Upgrades

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗

October 31, 2022

Upgrades

Via Benzinga

More Than $6 Million Bet On JELD-WEN Holding? 3 Stocks Insiders are Buying ↗

June 24, 2022

Although the US stocks closed higher on Thursday, there were a few notable insider trades.

Via Benzinga

Mid-Afternoon Market Update: Dow Dips 900 Points; AC Immune Shares Slide ↗

June 16, 2022

U.S. stocks traded lower toward the end of trading, after the Federal Reserve raised fed funds rates by 0.75% to a new target range of between 1.5% and 1.75% on Wednesday.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗

July 20, 2022

Upgrades

Via Benzinga

Mid-Day Market Update: Dow Tumbles 700 points; Advent Technologies Shares Spike Higher ↗

June 16, 2022

U.S. stocks traded lower midway through trading, after the Federal Reserve raised fed funds rates by 0.75% to a new target range of between 1.5% and 1.75% on Wednesday.

Via Benzinga

63 Biggest Movers From Yesterday ↗

June 17, 2022

Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the...

Via Benzinga

37 Stocks Moving In Thursday's Mid-Day Session ↗

June 16, 2022

Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares jumped 153% to $2.94 after the company announced it received notification of euro 782.1 million of funding from the Greek State for the...

Via Benzinga

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK ↗

June 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

82 Biggest Movers From Yesterday ↗

June 15, 2022

Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 14, 2022

Via Benzinga

41 Stocks Moving In Tuesday's Mid-Day Session ↗

June 14, 2022

Gainers Revlon, Inc. (NYSE: REV) rose 125.5% to $2.6499. Revlon’s stock dropped sharply on Monday after the company is reportedly expected to file for bankruptcy.

Via Benzinga

91 Biggest Movers From Friday ↗

June 13, 2022

Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.